The results demonstrated that HSE only displayed effects in reducing serum TAG levels and systolic blood pressure (SBP) without differences in glucose or other lipid profiles, BMI, insulin, hs-CRP, and MDA, suggesting some effects on hypertension and hypertriglyceridemia in MetS individuals, even with a lower dose and shorter time treatment compared with other studies [85]. The gene discussed is INS; the disease is metabolic syndrome.